NCT06965504View on ClinicalTrials.gov

INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

June 1, 2028

Conditions
Heart FailureCardiogenic ShockReduced Ejection Fraction Heart Failure
Interventions
DEVICE

Impella 5.5 SmartAssist

The intervention is Impella 5.5 with SmartAssist® support combined with heart failure guideline directed medical therapy (GDMT).

Trial Locations (5)

19104

University of Pennsylvania Health System, Philadelphia

32703

Centennial Medical Center, Nashville

33606

Tampa General Hospital, Tampa

555407

Abbott Northwestern, Minneapolis

08901

Rutgers-Robert Wood Johnson Medical School, New Brunswick

Sponsors

Lead Sponsor

Abiomed Inc.

Collaborators (1)

Johnson & Johnson
All Listed Sponsors
collaborator

Johnson & Johnson

INDUSTRY

lead

Abiomed Inc.

INDUSTRY

NCT06965504 - INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery | Biotech Hunter | Biotech Hunter